Corporate Profile
Cognition Therapeutics is a clinical-stage biopharmaceutical company leveraging our expertise in the σ-2 (sigma-2) receptor to develop innovative, small molecule therapeutics targeting age-related degenerative diseases. Our initial focus is on degenerative diseases of the CNS and retina such as Alzheimer’s disease, dementia with Lewy bodies and dry age-related macular degeneration.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
Aug 04, 2022
Aug 03, 2022
Jul 19, 2022
Events
Nov 29 - Dec 2, 2022
Jul 31 - Aug 4, 2022
Jun 16, 2022 at 12:30 PM EDT
Latest SEC Filings
Form | Filing date | Description |
---|---|---|
8-K | Report of unscheduled material events or corporate event |
|
4/A | Amendment to a previously filed 4 |
|
4/A | Amendment to a previously filed 4 |